Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The current study will determine whether a novel pharmacotherapy, BP1. 3656, affects laboratory alcohol self-administration in participants with alcohol use disorder (AUD).
The current study employs BP1.3656, a novel investigational compound with a track record for safety and tolerability in phase I clinical trials. When administered to mice, BP1.3656 was associated with increased metabolism of histamine and elevated brain dopamine and acetylcholine, suggestive of utility in psychiatric disorders including Alcohol Use Disorder (AUD).
This study is a Phase II laboratory-based trial of BP1 .3656 for AUD. 40 non-treatment seeking participants with AUD will be recruited. Participants will be randomly assigned to intervention with BP1 .3656 or placebo in a within-subject, crossover design. During each intervention period, outcome measures relating to alcohol motivation and self-administration will be assessed in the laboratory. It is hypothesized that relative to placebo, alcohol self-administration will be decreased by BP1 .3656.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Medication (BP1.3656) | Experimental | Participants will receive BP1.3656 in tablet form once daily at a dose of 30 µg/day for the first 4 days, followed by 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg. |
|
| Placebo pills | Placebo Comparator | Participants will receive matching placebo pills for 14 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BP1.3656 | Drug | BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg. |
| Measure | Description | Time Frame |
|---|---|---|
| Peak breath alcohol concentration (mg%) during free-access alcohol self-administration while taking study medication (BP1.3656). | Breath alcohol concentration (BrAC) test reading will be assessed | Measured during one self-administration session in the 2nd week of the 14-day study medication phase. |
| Peak breath alcohol concentration (mg%) during free-access alcohol self-administration while taking placebo. | Breath alcohol concentration (BrAC) test reading will be assessed | Measured during one self-administration session in the 2nd week of the 14-day placebo phase. |
| Motivation for alcohol completed during a progressive ratio alcohol self-administration session while taking study medication (BP1.3656). | Measured by number of button presses/work sets | Measured during one progressive-ratio self-administration session in the 2nd week of the 14-day medication phase |
| Motivation for alcohol completed during a progressive ratio alcohol self-administration session while taking placebo. | Measured by number of button presses/work sets | Measured during one progressive-ratio self-administration session in the 2nd week of the 14-day placebo-phase. |
| Measure | Description | Time Frame |
|---|---|---|
| Subjective effects of alcohol during free-access and progressive ratio self-administration sessions while taking study medication (BP1.3656), as measured by the Biphasic Alcohol Effects Scale (0-10 scoring) | Two subscales (stimulant and sedative) with a 0-10 scoring where higher scores for stimulant subscale indicate increased stimulated effects from alcohol, while higher scores for sedative subscale indicate more sedated effects from alcohol. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for Addiction and Mental Health | Toronto | Ontario | M5S 2S1 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| D000428 | Alcohol Drinking |
| D004327 | Drinking Behavior |
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
This will be a within-subjects, counterbalanced, crossover trial with a washout period. Participants will receive either placebo or the interventional drug BP1.3656 during the initial 14-day phase of the study and receive the other intervention during the second 14-day phase of the study. The washout period will last a minimum of 14 days.
Participants will come in to the laboratory on two separate days near the end of each intervention phase to complete alcohol self-administration sessions.
Not provided
Not provided
Not provided
| Placebo | Drug | Administered once daily in tablet form. |
|
| Measured during each of two alcohol self-administration sessions (free-access, progressive ratio) completed in the 2nd week of the 14-day medication phase. |
| Subjective effects of alcohol (maximum reported stimulation and sedation from alcohol) during free-access and progressive ratio self-administration sessions while taking placebo, as measured by the Biphasic Alcohol Effects Scale (0-10 scoring) | Two subscales (stimulant and sedative) with a 0-10 scoring where higher scores for stimulant subscale indicate increased stimulation, while higher scores for sedative subscale indicate more sedated effects from alcohol. | Measured during each of two alcohol self-administration sessions (free-access, progressive ratio) completed in the 2nd week of the 14-day placebo phase. |
| Self-reported craving after a priming dose of alcohol during free-access and progressive ratio self-administration sessions while taking BP1.3656, as measured by the Alcohol Urge Questionnaire (1-7 scoring) | 8 statements with score options ranging from Score of 1 = Strongly disagree to Score of 7 = Strongly Agree. Higher scores reflect greater craving. | Measured during each of 2 alcohol self-administration sessions (free-access, progressive ratio) completed in 2nd week of medication phase. |
| Self-reported craving after a priming dose of alcohol during free-access and progressive ratio self-administration sessions while taking placebo, as measured by the Alcohol Urge Questionnaire (1-7 scoring) | 8 statements with score options ranging from Score of 1 = Strongly disagree to Score of 7 = Strongly Agree. Higher scores reflect greater craving. | Measured during each of 2 alcohol self-administration sessions (free-access, progressive ratio) completed in 2nd week of placebo phase. |
| Safety and tolerability of BP1.3656 | Side effects of BP1.3656 will be assessed with the Systematic Assessment for Treatment Emergent Effects questionnaire (not reporting score on a scale) and the Pittsburgh Sleep Quality Index (19 items with 0-3 scoring, where higher scores indicate worse sleep quality). | During the free-access and progressive ratio sessions in the 2nd week of the 14-day study medication phase |
| Safety and tolerability of BP1.3656 | Side effects of BP1.3656 will be assessed with the Systematic Assessment for Treatment Emergent Effects questionnaire (not reporting score on a scale) and the Pittsburgh Sleep Quality Index (19 items with 0-3 scoring, where higher scores indicate worse sleep quality). | During the free-access and progressive ratio sessions in the 2nd week of the 14-day study placebo phase |
| Weekly alcohol consumption during treatment with BP1 .3656 | Drinks per week, as measured by the Timeline Follow-Back method | Measured during the 2nd week of the 14-day study medication phase |
| Weekly alcohol consumption during treatment with placebo | Drinks per week, as measured by the Timeline Follow-Back method | Measured during the 2nd week of the 14-day placebo phase |